Menu
ncarol.com
  • Home
  • Music
  • Books
  • Manufacturing
  • Asheville Music
  • Health
  • Book Release
  • Business
  • Technology
ncarol.com

The ROS1ders Issue RFA for $75K ROS1+ Cancer Innovation Award
ncarol.com/10256312

Trending...
  • FDA-Cleared Zeta TMS Robotic System Moves Toward Deployment as FDA, DARPA and Commercial Catalysts Converge: NRx Pharmaceuticals (N A S D A Q: NRXP)
  • Baird Medical Turns Global Expansion Into Tangible Growth: N A S D A Q: BDMD Posts 25% Revenue Surge as U.S. and International Markets Accelerate
  • Allstream Energy Partners Nominated in Multiple Categories for Fast Company's Best Workplaces for Innovators
Patient-founded nonprofit seeks to stimulate innovative research to improve outcomes for patients with ROS1+ cancers.

SACRAMENTO, Calif. - ncarol.com -- The ROS1ders is pleased to issue their 2024 Request for Application (RFA) to study ROS1-positive (ROS1+) cancer. The RFA is open to investigators who hold a doctorate degree and a faculty appointment at an academic or non-profit research institution anywhere in the world.

"While oral targeted therapies are approved to treat ROS1+ cancer, the drugs don't work for everyone, and they eventually stop working. We are committed to investing in research to improve patient outcomes," says Janet Freeman-Daily, MS, Engr, co-founder and president of The ROS1ders.

The ROS1+ Cancer Innovation Award aims to fund high-risk, high-reward projects focused on ROS1+ cancers. The one-year $75,000 seed grant can be used for pre-clinical, translational, or clinical research.

"Seed grants allow for the generation of initial data to support larger research endeavors," said D. Ross Camidge, MD, PhD, Professor of Medicine/Oncology at the University of Colorado and a member of The ROS1ders Scientific Advisory Board. "While some seeds fail, others grow into mighty trees - they can be the seeds of real breakthroughs."

More on ncarol.com
  • Notaron Expands Online Notarization Access Following Wisconsin Approval
  • Wings Air Helicopters Selected to Support VIP Transportation for Resorts World in New York
  • Scoop Social Co. Brings Its Signature Mobile Dessert Experience to Houston This October
  • Greater Charlotte ASTA Celebrates 2026 Queen City Travel Summit
  • The Social Capital Revolution Comes to Phoenix!

The award program uses a two-step application process. The deadline for a letter of intent is May 3, 2024. Those invited to submit a full application must provide it by August 4, 2024. For more information, visit https://theros1ders.org/seed-grant-program.

About the ROS1ders

Founded by patients in 2015 and incorporated in 2019, The ROS1ders is the largest global group of patients and family members living with ROS1+ cancer. It seeks to improve outcomes for all ROS1+ cancers through community, education, and research. Membership in their private Facebook group exceeds 1200 people from over 30 countries. The nonprofit is internationally recognized in the oncology and patient advocacy communities as experts in their disease. Its resources include a medically-vetted website and collaboration with international ROS1+ clinicians, researchers and industry. Please visit theros1ders.org to learn more.

More on ncarol.com
  • Lawsuit Alleges American Deli Food Caused Severe Illness, Acute Kidney Failure, And Eight-day Hospitalization
  • FBI/DoW plot uncovered to hurt Trump/Vance through encouraged "widespread" cybersecurity breaches and racketeering theft of $80m in USDA payments
  • Bettingbladet releases H1 2026 report on the Swedish online gambling market
  • Garage door installation or repair in Minnesota? Which makes more sense for your family?
  • Super Rooter Expands to 190 Plumbing, Sewer, and Drain Service Locations Across the United States

About ROS1+ Cancer
  • ROS1+ cancer is relatively rare, occurring in just 1-2% of non-small cell lung cancer (NSCLC). The incidence is thought to be similar in other types of cancer.
  • Biomarker testing for ROS1 fusions is recommended in guidelines for non-small cell lung cancer (NSCLC), but for few other cancers.
  • Patients are typically younger than the average NSCLC patient, have adenocarcinoma, and have no smoking history (a smoking history should not exclude patients from biomarker testing or targeted therapies).
  • Oral targeted therapies are the recommended first-line treatment for metastatic ROS1+NSCLC and have increased the survival of patients by years. However, these drugs eventually stop working due to acquired resistance. The mechanisms of resistance are not well understood.


Contact
Janet Freeman-Daily
***@theros1ders.org


Source: The ROS1ders, Inc.
Filed Under: Health

Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on ncarol.com
  • FDA-Cleared Zeta TMS Robotic System Moves Toward Deployment as FDA, DARPA and Commercial Catalysts Converge: NRx Pharmaceuticals (N A S D A Q: NRXP)
  • Baird Medical Turns Global Expansion Into Tangible Growth: N A S D A Q: BDMD Posts 25% Revenue Surge as U.S. and International Markets Accelerate
  • Black Mountain Meets "Human Error": KayeDinero on What Technology Can't Reproduce
  • As Brevard Heads Into Mountain Song Weekend, KayeDinero Brings a Different Kind of WNC Sound
  • Why Did KayeDinero Put Haywood Road Into a Song?
  • Shelter Structures America makes European debut at TEMPOR EXPO 2026 in Fulda, Germany
  • TekTone innovation meets patient care
  • HydroExcavation.com Relaunches With Exclusive Local Service Areas and Dedicated Hydrovac Manufacturer Directory
  • Sky Quarry Enters a Powerful New Chapter: Refinery Restart Emminent, Nevada Oil Initiative and Visibility Put (NAS DAQ: SKYQ) in the Spotlight
  • OneVizion Launches Vera AI, Bringing Connected Operational Context to Infrastructure Teams
  • P-Wave Press Announces Pushing the Wave 2025 by L.A. Davenport
  • DONGSHENG Titanium Recycling: Promoting a Closed-Loop Cycle for High-End Titanium Materials
  • Crawler Record for WordPress Version 1.0
  • French Camp Academy Releases New Video Inviting Individuals to Consider a Life of Service
  • Piedmont Crossing Celebrates 40 Years of Caring, Community, and Connection
  • LET US READ Documentary on Dyslexia and Literacy to Screen at TCL Chinese 6 in Hollywood
  • ChatGPT Leans Mostly on Firms' Own Websites to Decide Which Environmental Consultant to Recommend
  • What Does "Human Error" Sound Like North of Asheville? KayeDinero Brings New Era to Weaverville
  • Before Asheville, There Was Cherokee: KayeDinero Reveals Where Her Carolina Chapter Really Began
  • Profit at the Window: Free Webinar Helps Interior Designers Turn Window Treatments Into Revenue
_catLbl0 _catLbl1

Popular on ncarol.com

  • Mito Health Passes One Million Lab Tests, Expands to Seven Categories of Preventive Health Testing - 156
  • Parksy (parksy.com) Tackles the Most Common Parking Problem Nobody Talks About: Finding the Car Again - 155
  • Free JavaScript Charting Library ProEssentialsJS Permits Commercial Use. Highcharts, SciChart and LightningChart Free Tiers Do Not - 139
  • 5X Gross Margin Improvement to Beat EPS Consensus; $54.6 Million 10-Year Contract Award Puts Cybersecurity Leader on Path to a $30 Million Run Rate - 133
  • BumbleBeeSmart Launches Dedicated Sensory Wall Panels Collection for Adults, Memory Care and Senior Living - 123
  • Robert DeMaio, Phinge CEO to Speak at 30th IIPLA 2026 on Securing IP, User Data & Digital Sovereignty via Verified App-less Tech. Attend the Live Q&A! - 123
  • Bspin Launches Lightning-Fast Crypto Gaming Expansion With Sportsbook, Poker, VIP Rewards, and Bitcoin Lightning Network Integration - 122
  • From Temecula Wine Country to Canyon Lake: Parkway Construction Transforms Outdoor Spaces for Inland Homeowners - 121
  • Project CIVICA Report Finds 10,680 Non-Citizen Indicators on New York Voter Rolls — Including 88 Records with Recent Voting History - 120
  • Space Ambitions Expanding as New Testing Builds on NASA Results and Targets MEO, GEO and Next-Generation Orbital Markets: Ascent Solar Technologies - 112

Similar on ncarol.com

  • International Society of Medical AI Convenes Global Faculty in Florence for ISMAI 2026
  • Lawsuit Alleges American Deli Food Caused Severe Illness, Acute Kidney Failure, And Eight-day Hospitalization
  • European Patent for ALS Program Expands the Story: HOPE Deploys Robotic TMS & FDA Commercialization Path Advances: NRx Pharmaceuticals: NAS DAQ: NRXP
  • Congressman Chuck Edwards (NC-11) Presents ReadyCommunities Partnership 2026 National Service Award to Local Businessman / US Air Force Veteran
  • White Coat Financial Partners Announces Launch of Next Generation Practice Optimization Software
  • FDA-Cleared Zeta TMS Robotic System Moves Toward Deployment as FDA, DARPA and Commercial Catalysts Converge: NRx Pharmaceuticals (N A S D A Q: NRXP)
  • Baird Medical Turns Global Expansion Into Tangible Growth: N A S D A Q: BDMD Posts 25% Revenue Surge as U.S. and International Markets Accelerate
  • French Camp Academy Releases New Video Inviting Individuals to Consider a Life of Service
  • Piedmont Crossing Celebrates 40 Years of Caring, Community, and Connection
  • Qscription Technologies and NEOPATHOLOGY CORP. Sign MOU to Bring FDA-Cleared Lung Imaging AI into U.S. Clinical Practice
Copyright © 2026 ncarol.com | Contact Us | Privacy Policy | Terms of Service | Contribute